Payment overview · 2025
General Payments
$1,497.81
80 reported records · 23 companies
Healthcare provider profile · identity verified
William Eugene Alldredge, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUSCALOOSA, AL · NPI 1801904636
Verified facts
What the public records show
CMS Open Payments records show William Eugene Alldredge, M.D. received $1,497.81 in general payments during 2025 across 80 reported records.
Novo Nordisk Inc accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1224 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $187.04 | 12.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.02 | 11.8% | 9 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $129.16 | 8.6% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $126.65 | 8.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.49 | 8.3% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.23 | 7.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.78 | 6.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.05 | 5.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.53 | 4.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.20 | 4.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.08 | 2.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.99 | 2.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $34.94 | 2.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.74 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.07 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.82 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.15 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.43 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.36 | 1.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $19.91 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.49 | 1.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.31 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,497.81 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.97 | 7 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $129.16 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $126.65 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.04 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.81 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.81 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.60 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.85 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.44 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.05 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.53 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.20 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.66 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.66 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.12 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.99 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.07 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| VIIBRYD Normalized: viibryd |
Drug | ABBVIE INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.68 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1224 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 227 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
336 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
336 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
227 | 26 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
142 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
144 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
227 | 26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
227 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1224 | 143 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1911 | 382 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1857 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 1638 | 340 |
| Gabapentin | Gabapentin | 1543 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1391 | 236 |
| Trazodone Hcl | Trazodone Hcl | 1233 | 224 |
| Eliquis | Apixaban | 1224 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1193 | 257 |
| Potassium Chloride | Potassium Chloride | 1109 | 208 |
| Furosemide | Furosemide | 826 | 179 |
| Lisinopril | Lisinopril | 826 | 204 |
| Escitalopram Oxalate | Escitalopram Oxalate | 819 | 151 |
| Losartan Potassium | Losartan Potassium | 812 | 202 |
| Omeprazole | Omeprazole | 808 | 216 |
| Metformin Hcl | Metformin Hcl | 791 | 168 |
| Meloxicam | Meloxicam | 732 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 730 | 142 |
| Baclofen | Baclofen | 713 | 164 |
| Carvedilol | Carvedilol | 688 | 152 |
| Simvastatin | Simvastatin | 681 | 165 |
| Buspirone Hcl | Buspirone Hcl | 653 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 632 | 136 |
| Clopidogrel | Clopidogrel Bisulfate | 534 | 100 |
| Quetiapine Fumarate | Quetiapine Fumarate | 518 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 518 | 143 |
| Pravastatin Sodium | Pravastatin Sodium | 472 | 115 |
| Montelukast Sodium | Montelukast Sodium | 446 | 123 |
| Fluticasone Propionate | Fluticasone Propionate | 444 | 155 |
| Mirtazapine | Mirtazapine | 438 | 78 |
| Famotidine | Famotidine | 434 | 88 |
| Donepezil Hcl | Donepezil Hcl | 415 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 403 | 105 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 395 | 57 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 383 | 42 |
| Sertraline Hcl | Sertraline Hcl | 381 | 64 |
| Ondansetron Hcl | Ondansetron Hcl | 378 | 148 |
| Levetiracetam | Levetiracetam | 376 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 375 | 78 |
| Memantine Hcl | Memantine Hcl | 366 | 50 |
| Allopurinol | Allopurinol | 357 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 357 | 48 |
| Alprazolam | Alprazolam | 356 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 354 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 353 | 53 |
| Jardiance | Empagliflozin | 336 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 320 | 88 |
| Tramadol Hcl | Tramadol Hcl | 311 | 85 |
| Clonazepam | Clonazepam | 284 | 45 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 278 | 29 |
| Lorazepam | Lorazepam | 261 | 47 |
| Clonidine Hcl | Clonidine Hcl | 260 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 255 | 51 |
| Xarelto | Rivaroxaban | 253 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 239 | 58 |
| Glimepiride | Glimepiride | 235 | 63 |
| Pregabalin | Pregabalin | 232 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 99 |
| Warfarin Sodium | Warfarin Sodium | 229 | 22 |
| Rexulti | Brexpiprazole | 227 | 26 |
| Ozempic | Semaglutide | 222 | 48 |
| Divalproex Sodium | Divalproex Sodium | 221 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 213 | 54 |
| Metformin Hcl Er | Metformin Hcl | 209 | 44 |
| Bupropion Xl | Bupropion Hcl | 205 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 184 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 181 | 42 |
| Januvia | Sitagliptin Phosphate | 177 | 26 |
| Spironolactone | Spironolactone | 174 | 38 |
| Bumetanide | Bumetanide | 169 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 166 | 35 |
| Meclizine Hcl | Meclizine Hcl | 164 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 49 |
| Enalapril Maleate | Enalapril Maleate | 161 | 38 |
| Cefuroxime | Cefuroxime Axetil | 157 | 133 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 157 | 30 |
| Ezetimibe | Ezetimibe | 154 | 47 |
| Atenolol | Atenolol | 150 | 38 |
| Myrbetriq | Mirabegron | 149 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 148 | 67 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 144 | 11 |
| Entresto | Sacubitril/Valsartan | 142 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 33 |
| Farxiga | Dapagliflozin Propanediol | 141 | 36 |
| Glipizide | Glipizide | 141 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 138 | 18 |
| Mupirocin | Mupirocin | 138 | 64 |
| Nystatin | Nystatin | 138 | 65 |
| Ibuprofen | Ibuprofen | 136 | 32 |
| Oxcarbazepine | Oxcarbazepine | 134 | 13 |
| Sucralfate | Sucralfate | 134 | 27 |
| Latanoprost | Latanoprost | 133 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 132 | 32 |
| Aripiprazole | Aripiprazole | 131 | 23 |
| Methocarbamol | Methocarbamol | 131 | 39 |
| Levofloxacin | Levofloxacin | 130 | 99 |
| Finasteride | Finasteride | 124 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 122 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 23 |
| Lacosamide | Lacosamide | 120 | 14 |
| Fenofibrate | Fenofibrate | 118 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 118 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 117 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 116 | 26 |
| Mounjaro | Tirzepatide | 115 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 29 |
| Olanzapine | Olanzapine | 112 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 111 | 90 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 110 | 26 |
| Celecoxib | Celecoxib | 109 | 19 |
| Risperidone | Risperidone | 109 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 107 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 105 | 24 |
| Prednisone | Prednisone | 103 | 32 |
| Fentanyl | Fentanyl | 98 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 95 | 37 |
| Diltiazem Hcl | Diltiazem Hcl | 92 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 24 |
| Chlorthalidone | Chlorthalidone | 89 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 87 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 28 |
| Fluconazole | Fluconazole | 83 | 57 |
| Ceftriaxone | Ceftriaxone Sodium | 81 | 34 |
| Metoclopramide Hcl | Metoclopramide Hcl | 80 | 17 |
| Ramipril | Ramipril | 78 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 73 | 11 |
| Estradiol | Estradiol | 72 | 22 |
| Gemfibrozil | Gemfibrozil | 72 | 12 |
| Valsartan | Valsartan | 72 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 71 | 13 |
| Midodrine Hcl | Midodrine Hcl | 71 | 17 |
| Torsemide | Torsemide | 71 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 42 |
| Humulin R | Insulin Regular, Human | 70 | 17 |
| Naproxen | Naproxen | 70 | 28 |
| Glipizide Er | Glipizide | 69 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 13 |
| Topiramate | Topiramate | 66 | 16 |
| Cephalexin | Cephalexin | 64 | 54 |
| Lansoprazole | Lansoprazole | 63 | 18 |
| Phenobarbital | Phenobarbital | 63 | suppressed |
| Metolazone | Metolazone | 62 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 41 |
| Sodium Chloride | 0.9 % Sodium Chloride | 60 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | suppressed |
| Colchicine | Colchicine | 59 | 32 |
| Cefdinir | Cefdinir | 58 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 15 |
| Gemtesa | Vibegron | 56 | 11 |
| Digoxin | Digoxin | 55 | 11 |
| Lamotrigine | Lamotrigine | 55 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 53 | suppressed |
| Hydrocortisone | Hydrocortisone | 53 | 15 |
| Novolin R | Insulin Regular, Human | 53 | 26 |
| Benazepril Hcl | Benazepril Hcl | 52 | 12 |
| Doxepin Hcl | Doxepin Hcl | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 15 |
| Primidone | Primidone | 51 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 49 | suppressed |
| Lactulose | Lactulose | 49 | 15 |
| Ondansetron Odt | Ondansetron | 49 | 25 |
| Fenofibrate | Fenofibrate,micronized | 47 | 12 |
| Promethazine Hcl | Promethazine Hcl | 47 | 25 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 12 |
| Linzess | Linaclotide | 46 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 16 |
| Austedo | Deutetrabenazine | 43 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Dutasteride | Dutasteride | 42 | 11 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 15 |
| Scopolamine | Scopolamine | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 13 |
| Creon | Lipase/Protease/Amylase | 39 | suppressed |
| Novolog | Insulin Aspart | 38 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 38 | suppressed |
| Rivastigmine | Rivastigmine | 38 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 37 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | 12 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Nystop | Nystatin | 37 | 16 |
| Lidocaine Hcl | Lidocaine Hcl | 36 | 25 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 12 |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Olanzapine Odt | Olanzapine | 33 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 20 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 32 | 27 |
| Lithium Carbonate | Lithium Carbonate | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 32 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 32 | 15 |
| Haloperidol | Haloperidol | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 11 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 15 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Xtampza Er | Oxycodone Myristate | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Ramelteon | Ramelteon | 25 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Daptomycin | Daptomycin | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Indomethacin | Indomethacin | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Leflunomide | Leflunomide | 22 | suppressed |
| Lumigan | Bimatoprost | 22 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Victoza 3-Pak | Liraglutide | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,sf 0.5ml | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 11 |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Mesalamine Er | Mesalamine | 15 | suppressed |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 14 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Symproic | Naldemedine Tosylate | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,497.81 · 80 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OFEV, Ozempic, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, VIIBRYD, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error